Reading and Resources
Additional Reading:
American Academy of Pediatrics (AAP) (2023): Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity
https://publications.aap.org/pediatrics/article/151/2/e2022060640/190443/Clinical-Practice-Guideline-for-the-Evaluation-and
American Association of Clinical Endocrinology (AACE) (2025): Evaluation and treatment of adults with obesity/adiposity-based chronic disease
https://www.endocrinepractice.org/article/S1530-891X(25)00977-2/fulltext
American Diabetes Association (ADA) (2026): Obesity and weight management for the prevention and treatment of diabetes: Standards of Care in Diabetes–2026
https://diabetesjournals.org/care/article/49/Supplement_1/S166/163915/8-Obesity-and-Weight-Management-for-the-Prevention
American Diabetes Association (ADA) (2026): Obesity and weight management for the prevention and treatment of diabetes: Standards of Care in Diabetes–2026
https://diabetesjournals.org/care/article/49/Supplement_1/S166/163915/8-Obesity-and-Weight-Management-for-the-Prevention
American Gastroenterological Association (AGA) (2022): Clinical practice guidelines on pharmacological interventions for adults with obesity
https://www.gastrojournal.org/article/S0016-5085(22)01026-5/fulltext?referrer=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F
American Heart Association (AHA) (2021): Obesity and cardiovascular disease, a scientific statement from the American Heart Association
https://www.ahajournals.org/doi/10.1161/CIR.0000000000000973
American Society for Metabolic and Bariatric Surgery (ASMBS) and the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) (2022): Indications for metabolic and bariatric surgery
https://linkinghub.elsevier.com/retrieve/pii/S1550-7289(22)00641-4
Lilly USA, LLC. Disease Education Resources: Obesity.
https://medical.lilly.com/us/diseases/disease-education-resources/obesity/obesity
National Institute for Health and Care Excellence (NICE) (2025): Overweight and obesity management
https://www.nice.org.uk/guidance/ng246
World Health Organization (WHO) (2025): WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults
https://app.magicapp.org/#/guideline/LrRxrL
Additional Reading:
- Darlenski R, Mihaylova V, Handjieva-Darlenska T. The link between obesity and the skin. Front Nutr. 2022;9:855573. https://pubmed.ncbi.nlm.nih.gov/35369048/
- Elmaleh-Sachs A, Schwartz JL, Bramante CT, et al. Obesity management in adults: A review. JAMA. 2023;330(20):2000-2015. https://pubmed.ncbi.nlm.nih.gov/38015216/
- Gkrinia EMM, Belančić A. The mechanisms of chronic inflammation in obesity and potential therapeutic strategies: A narrative review. Curr Issues Mol Biol. 2025;47(5):357. https://pubmed.ncbi.nlm.nih.gov/40699756/
- Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(25 Suppl 2):S102-38. https://pubmed.ncbi.nlm.nih.gov/24222017/
- Kaazan P, Seow W, Yong S, et al. The impact of obesity on inflammatory bowel disease. Biomedicines. 2023;11(12):3256. https://pubmed.ncbi.nlm.nih.gov/38137477/
- Kadouh H, Chedid V, Halawi H, et al. GLP-1 analog modulates appetite, taste preference, gut hormones, and regional body fat stores in adults with obesity. J Clin Endocrinol Metab. 2020;105(5):1552-1563. https://pubmed.ncbi.nlm.nih.gov/31665455/
- Kellner DA, Dente E, Tran V, et al. Effect of glucagon-like peptide 1 receptor agonists on patients with rheumatoid arthritis. ACR Open Rheumatol. 2025;7(9):e70103. https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr2.70103
- Kumthekar A, Ogdie A. Obesity and psoriatic arthritis: A narrative review. Rheumatol Ther. 2020;7(3):447-456. https://pubmed.ncbi.nlm.nih.gov/32495313/
- Moore PW, Malone K, VanValkenburg D, et al. GLP-1 agonists for weight loss: Pharmacology and clinical implications. Adv Ther. 2023;40(3):723-742. https://pubmed.ncbi.nlm.nih.gov/36566341/
- Pagnini C, Uregsi R, De Paolo M, et al. Obesity and weight loss diets in inflammatory bowel disease patients: what physicians should know. J Gastrointestin Liver Dis. 2024;33: 542-551. https://pubmed.ncbi.nlm.nih.gov/39733306/
- Palanivel JA, Millington GWM. Obesity-induced immunological effects on the skin. Skin Health Dis. 2023;3(3):e160. https://pubmed.ncbi.nlm.nih.gov/37275420/
- Scheiber A, Mank V. Anti-inflammatory diets. [Updated 2023 Oct 28]. In: StatPearls Innternet].Treasure Island (FL): StatPearls Publishing; 2025 Jan-. https://www.ncbi.nlm.nih.gov/books/NBK597377/
- Singh S, Dulai P, Zarrinpar A, et al. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol. 2017;14(2):110–121. https://pubmed.ncbi.nlm.nih.gov/27899815/
- Singh S, Loftus E, Limketkai B, et al. AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis. Gastroenterology. 2024;167:1307–1343. https://pubmed.ncbi.nlm.nih.gov/39572132/
- Tournadre A, Beauger M. Weight loss affects disease activity and treatment response in inflammatory rheumatic diseases. Joint Bone Spine. 2024;91(3):105647. https://pubmed.ncbi.nlm.nih.gov/37783311/
- Wong HJ, Sim B, Teo YH, et al. Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: A systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials. Diabetes Care. 2025;48(2):292-300. https://pubmed.ncbi.nlm.nih.gov/39841962/
- Yearwood L, Masood W. Behavioral approaches to obesity treatment. [Updated 2024 Jan 31]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. https://www.ncbi.nlm.nih.gov/books/NBK570565/
All URL’s accessed 1/14/26.
